Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.56 |
| ▸ | WNT3A | P56704 | 1/20 | 0.56 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25203201 | 0.89 | RAB9A (0.70) | SMN1; SMN2RAB9ANPC1LMNAHPGD | |
| SCHEMBL25231300 | 0.88 | CTNNB1 (0.73) | SMN1; SMN2RAB9ANPC1LMNAHPGD | |
| SCHEMBL7812122 | 0.82 | KMT2A (0.60) | SMN1; SMN2RAB9ANPC1LMNAHPGD | |
| SCHEMBL109197 | 0.81 | ALDH1A1 (0.64) | SMN1; SMN2RAB9ANPC1LMNAHPGD | |
| SCHEMBL14518414 | 0.81 | ALDH1A1 (0.70) | SMN1; SMN2RAB9ANPC1LMNAHPGD | |
| SCHEMBL11694008 | 0.79 | TDP1 (0.65) | SMN1; SMN2RAB9ANPC1LMNAHPGD | |
| SCHEMBL11696819 | 0.79 | KMT2A (0.59) | SMN1; SMN2RAB9ANPC1LMNAHPGD | |
| SCHEMBL1554690 | 0.79 | CTNNB1 (0.66) | SMN1; SMN2RAB9ANPC1LMNAHPGD | |
| SCHEMBL392612 | 0.78 | NPC1 (0.62) | SMN1; SMN2RAB9ANPC1LMNAHPGD | |
| SCHEMBL4821161 | 0.77 | CTNNB1 (0.61) | SMN1; SMN2RAB9ANPC1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2202215-B1 | Novel process for the synthesis of (E)-Stilbene derivatives which makes it possible to obtain resveratrol and piceatannol | CLARIANT SPECIALTY FINE CHEM F (FR) | 2013-10-02 | — | — | EP | disclosed |
| EP-2049459-B1 | NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL | CLARIANT SPECIALTY FINE CHEM F (FR) | 2013-10-02 | — | — | EP | disclosed |
| US-8101804-B2 | Process for the synthesis of (E)-stilbene derivatives which makes it possible to obtain resveratrol and piceatannol | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2012-01-24 | — | — | US | disclosed |
| EP-2202215-A2 | Novel process for the synthesis of (E)-Stilbene derivatives which makes it possible to obtain resveratrol and piceatannol | Clariant Specialty Fine Chemicals (France) (FR) | 2010-06-30 | — | — | EP | disclosed |
| US-20100004483-A1 | Novel Process For The Synthesis Of (E)-Stilbene Derivatives Which Makes It Possible To Obtain Resveratrol And Piceatannol | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2010-01-07 | — | — | US | disclosed |
| EP-2049459-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL | Clariant Specialty Fine Chemicals (France) (FR) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012321-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004483-A1 | Novel Process For The Synthesis Of (E)-Stilbene Derivatives Which Makes It Possible To Obtain Resveratrol And Piceatannol | SQLE, SUCLA2, SORD | SMN1; SMN2 4268/4885RAB9A 3458/4885NPC1 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.